Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2017

View Archived Issues

AG-348 well tolerated in updated data from phase II DRIVE PK study

WHSC1 revealed as a promising therapeutic target for ALL

Characterization of next-generation anti-CD19 half-life extended BiTE antibody

TP-0903 demonstrates promising in vitro and in vivo activity

NuCana BioMed patents adenosine derivatives for cancer

RedHill Biopharma begins phase IIa study of Yeliva in cholangiocarcinoma

FGFR inhibitors reported in Shanghai Allist Pharmaceutical patent

Enlibrium describes biguanide derivatives

Phase II study of anabasum in SLE begins

Arrowhead Pharmaceuticals seeks approval for phase I/II study of HBV drug

FDA issues complete response letter for Agile's Twirla

Mallinckrodt to acquire Sucampo Pharmaceuticals

FDA grants fast track designation for VAL-083 in recurrent glioblastoma

FDA updates Tasigna label to include information on stopping therapy in certain CML patients

Ono submits supplemental application for Opdivo in Japan

Poxel and Sumitomo Dainippon Pharma initiate phase III program for imeglimin

Arno Therapeutics sells remaining assets

Soliris approved in Japan for the treatment of patients with generalized myasthenia gravis

CG-806 receives orphan drug designation from FDA for treatment of AML

FDA grants fast track designation to cannabidiol oral solution for Prader-Willi syndrome

Agios submits NDA for ivosidenib to treat relapsed/refractory AML with an IDH1 mutation

Portola Pharmaceuticals provides update on BLA for AndexXa

Summit acquires Discuva and obtains innovative antibiotic discovery and development platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...